Test Code:
Synonym(s):
ALK mutational testing in neuroblastomas is offered preemptively by our department both as a prognostic biomarker, and a potential predictive biomarker for response to crizotinib. Patients with neuroblastomas harboring the ALK F1174L mutation have been reported to have a worse prognosis than those with wild-type ALK1. Preclinical in vitro studies have shown that the presence of the ALK R1275Q mutation correlates with sensitivity to crizotinib, while the ALK F1174L mutation correlates with resistance to crizotinib.
{0}
{1}
Subscribe to our mailing list to get the updates to your email inbox...